Back to search results

Imaging CXCR4 in Blood and Solid Tumors with [68Ga]-Pentixafor-PET

This study is looking at how a special imaging agent called [68Ga]-Pentixafor is taken up by certain blood cancers and other conditions. These include non-Hodgkin lymphoma, multiple myeloma, and histiocytic neoplasms (like Erdheim-Chester disease). Researchers will inject [68Ga]-Pentixafor into participants and then use PET/CT scans to see where it goes. The main goal is to measure the amount of this agent in tumors. This study is for adults aged 18 and older who have been diagnosed with one of these conditions. The study aims to enroll 30 participants, but its current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 30 participants. It is not specified if it is randomized or blinded.
What's involved
Participants will receive an intravenous injection of [68Ga]-Pentixafor. The study measures tumor standard uptake value (SUV) at 1 year.
Compensation
Not stated in the trial record.
Follow-up
Tumor standard uptake value (SUV) will be measured at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05093335

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Recruiting
EARLY_PHASE1Ages 18+InterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~30 participants
Updated 2026-02-05 on ClinicalTrials.gov
What's tested:[68Ga]-Pentixafor

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tumor standard uptake value (SUV)
Measured over 1 year

Conditions

Non-Hodgkin Lymphoma
Multiple Myeloma
Histiocytic Neoplasms
Erdheim-Chester Disease
Rosai-Dorfman Disease

Explore related trials

Adrenal Cortical NeoplasmErdheim-Chester DiseaseHematologic NeoplasmLangerhans Cell HistiocytosisMeningiomaMultiple MyelomaMungan SyndromeNon-Hodgkin LymphomaRosai-Dorfman-Destombes DiseaseSmoldering Multiple MyelomaSolid Neoplasm

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Anton Nosov, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Anton Nosov, MD
[email protected]
212-639-8575
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria
Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD)
MGUS/SMM or MM according to IMWG definitions
Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with Cushing's disease.
Age ≥18
Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \& Guidelines) from assays obtained \<2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention
MSKCC patients

Exclusion

Breast-feeding
History of renal functional disorders (chronic kidney disease with eGFR\<30)
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)

What this trial measures

  • Tumor standard uptake value (SUV)1 year

    Means and 95% confidence intervals for \[68Ga\]-Pentixafor standardized uptake values (SUV) and tumor-to-background ratios (TBR) of tumors will be recorded. Uptake will be measured in tumors.